Dexilant 30mg 14 capsules — Made in Italy — Free Delivery

Product description

Modified release capsules with an opaque blue cap and an opaque gray body; the cap is engraved with the "TAP" logo in dark gray ink, and the body - the inscription "30". The contents of the capsules are white to almost white granules.

Indications for use

• treatment of erosive esophagitis of any severity;
• supportive care after treatment of erosive esophagitis and relief from heartburn;
• symptomatic treatment of gastroesophageal reflux disease GERD (i.e. NERD - non-erosive reflux disease);

Contraindications

• hypersensitivity to any component of the preparation;
• concomitant use with HIV protease inhibitors (atazanavir, nelfinavir);
• age under 18;
• pregnancy, lactation.

The preparation contains sucrose, therefore its use is not recommended for patients with hereditary fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase deficiency.

Take with care

• patients taking tacrolimus;
• patients taking inhibitors of the isoenzyme CYP2C19, such as fluvoxamine patients taking warfarin, under the control of prothrombin time and MHO;
• patients taking methotrexate.

Composition of 1 capsule

Active ingredients: dexlansoprazole 30 mg

Excipients:

granulated sugar - 28.8 mg (including sucrose 18-26.352 mg, corn starch 2.448-10.8 mg),

magnesium carbonate - 11.5 mg,

sucrose - 41.5 mg,

low-substituted hyprolosis - 8.64 mg,

hyprolosis - 0.34 mg,

hypromellose 2910 - 7.54 mg,

talc - 16.64 mg,

titanium dioxide - 5.5 mg,

dispersion of methacrylic acid copolymer - 9.66 mg (including methacrylic acid - 4.4436 mg, ethyl acrylate - 4.2504 mg, sodium lauryl sulfate - 0.2254 mg, polysorbate-80 - 0.7406 mg),

macrogol 8000 - 0.96 mg,

polysorbate-80 - 0.44 mg,

colloidal silicon dioxide - 0.09 mg,

methacrylic acid and methyl methacrylate copolymer [1: 2] - 15.95 mg,

methacrylic acid and methyl methacrylate copolymer [1: 1] - 5.32 mg,

triethyl citrate - 2.12 mg.

Capsule shell composition:

carrageenan - 0.192-0.624 mg,

potassium chloride - 0.144-0.48 mg,

titanium dioxide - 2.4768 mg,

dye FD & C blue No. 2 aluminum varnish - 0.3456 mg,

iron dye black oxide - 0.0576 mg,

hypromellose - q.s. up to 48 mg,

peeled gray ink for marking - trace amounts.

Ink composition: iron dye red oxide, iron oxide yellow dye, FD & C blue No. 2 dye aluminum varnish, carnauba wax, shellac, glyceryl monooleate.

special instructions

Before starting treatment with dexlansoprazole, the possibility of malignant neoplasm should be excluded, since the preparation can mask symptoms and delay the correct diagnosis.

If symptoms persist despite adequate treatment, further evaluation should be undertaken.

When taking proton pump inhibitors, which include dexlansoprazole, the risk of gastrointestinal infections, accompanied by diarrhea, caused by Clostridium difficile bacteria, increases, especially in hospitalized patients. This must be taken into account if the patient's condition does not improve with the treatment of diarrhea.

Patients in this case are advised to take the minimum effective dose of dexlansoprazole with the shortest duration of treatment.

In patients receiving high doses of the preparation or with prolonged therapy with proton pump inhibitors (PPIs) for a year or more, the risk of osteoporotic fractures of the hips, hands and spine increases. Patients at risk of osteoporotic fractures should adhere to the recommended dosages (see section "Dosage and Administration").

In rare cases, patients experienced symptomatic and asymptomatic hypomagnesemia when taking PPI preparations for at least three months, and in most cases, when taking it for a year. Symptoms of hypomagnesemia are tetany, arrhythmia, and seizures. Treatment - magnesium replacement and withdrawal of PPI preparations. In patients who need long-term treatment or who are concurrently taking PPI preparations with digoxin or other preparations that can cause hypomagnesemia (for example, diuretics), it is necessary to monitor the concentration of magnesium in the serum before and during treatment.

Dose adjustment

In case of impaired renal function: dose adjustment in patients with impaired renal function is not required.

In case of impaired liver function: in patients with moderate hepatic impairment (class B but Child-Pugh), the daily dose should not exceed 30 mg of dexlansoprazole.

There are no clinical data on the use of the preparation in patients with severe disorders (class C according to Child-Pugh).

No dose adjustment is required in patients with mild liver dysfunction (Child-Pugh class A).

Use in the elderly: dose adjustment in elderly patients is not required.

Influence on the ability to drive vehicles / mechanisms.

Due to the likelihood of dizziness and visual impairment, you should refrain from driving vehicles and other mechanisms that require increased attention.